Publication: Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV- 1 subtypes correlate with decreased risk of HIV-1 infection.
Accepted Date
2013-12-16
Issued Date
2014-02-04
Resource Type
Language
eng
ISSN
1932-6203 (electronic)
Rights
Mahidol University
Rights Holder(s)
PloS one
Bibliographic Citation
Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, et al. Vaccine-induced IgG antibodies to V1V2 regions of multipleHIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014 Feb 4;9(2):e87572.
Suggested Citation
Zolla-Pazner, Susan, deCamp, Allan, Gilbert, Peter B., Williams, Constance, Yates, Nicole L., Williams, William T., Howington, Robert, Fong, Youyi, Morris, Daryl E., Soderberg, Kelly A., Irene, Carmela, Reichman, Charles, Pinter, Abraham, Parks, Robert, Punnee Pitisuttithum, พรรณี ปิติสุทธิธรรม, Jaranit Kaewkungwal, จรณิต แก้วกังวาล, Supachai Rerks-Ngarm, ศุภชัย ฤกษ์งาม, Sorachai Nitayaphan, สรชัย นิตยพันธ, Andrews, Charla, O’Connell, Robert J., Yang, Zhi-yong, Nabel, Gary J., Kim, Jerome H., Michael, Nelson L., Montefiori, David C., Liao, Hua-Xin, Haynes, Barton F., Tomaras, Georgia D. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV- 1 subtypes correlate with decreased risk of HIV-1 infection.. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, et al. Vaccine-induced IgG antibodies to V1V2 regions of multipleHIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014 Feb 4;9(2):e87572.. doi:10.1371/journal.pone.0087572 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/764
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV- 1 subtypes correlate with decreased risk of HIV-1 infection.
Author(s)
Zolla-Pazner, Susan
deCamp, Allan
Gilbert, Peter B.
Williams, Constance
Yates, Nicole L.
Williams, William T.
Howington, Robert
Fong, Youyi
Morris, Daryl E.
Soderberg, Kelly A.
Irene, Carmela
Reichman, Charles
Pinter, Abraham
Parks, Robert
Punnee Pitisuttithum
พรรณี ปิติสุทธิธรรม
Jaranit Kaewkungwal
จรณิต แก้วกังวาล
Supachai Rerks-Ngarm
ศุภชัย ฤกษ์งาม
Sorachai Nitayaphan
สรชัย นิตยพันธ
Andrews, Charla
O’Connell, Robert J.
Yang, Zhi-yong
Nabel, Gary J.
Kim, Jerome H.
Michael, Nelson L.
Montefiori, David C.
Liao, Hua-Xin
Haynes, Barton F.
Tomaras, Georgia D.
deCamp, Allan
Gilbert, Peter B.
Williams, Constance
Yates, Nicole L.
Williams, William T.
Howington, Robert
Fong, Youyi
Morris, Daryl E.
Soderberg, Kelly A.
Irene, Carmela
Reichman, Charles
Pinter, Abraham
Parks, Robert
Punnee Pitisuttithum
พรรณี ปิติสุทธิธรรม
Jaranit Kaewkungwal
จรณิต แก้วกังวาล
Supachai Rerks-Ngarm
ศุภชัย ฤกษ์งาม
Sorachai Nitayaphan
สรชัย นิตยพันธ
Andrews, Charla
O’Connell, Robert J.
Yang, Zhi-yong
Nabel, Gary J.
Kim, Jerome H.
Michael, Nelson L.
Montefiori, David C.
Liao, Hua-Xin
Haynes, Barton F.
Tomaras, Georgia D.
Corresponding Author(s)
Other Contributor(s)
Abstract
In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to
variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an
inverse correlate of risk of HIV-1 infection. To determine if V1V2-specific Abs
cross-react with V1V2 from different HIV-1 subtypes, if the nature of the V1V2
antigen used to asses cross-reactivity influenced infection risk, and to identify
immune assays for upcoming HIV-1 vaccine efficacy trials, new V1V2-scaffold
antigens were designed and tested. Protein scaffold antigens carrying the V1V2
regions from HIV-1 subtypes A, B, C, D or CRF01_AE were assayed in pilot studies,
and six were selected to assess cross-reactive Abs in the plasma from the
original RV144 case-control cohort (41 infected vaccinees, 205 frequency-matched
uninfected vaccinees, and 40 placebo recipients) using ELISA and a binding Ab
multiplex assay. IgG levels to these antigens were assessed as correlates of risk
in vaccine recipients using weighted logistic regression models. Levels of Abs
reactive with subtype A, B, C and CRF01_AE V1V2-scaffold antigens were all
significant inverse correlates of risk (p-values of 0.0008-0.05; estimated odds
ratios of 0.53-0.68 per 1 standard deviation increase). Thus, levels of
vaccine-induced IgG Abs recognizing V1V2 regions from multiple HIV-1 subtypes,
and presented on different scaffolds, constitute inverse correlates of risk for
HIV-1 infection in the RV144 vaccine trial. The V1V2 antigens provide a link
between RV144 and upcoming HIV-1 vaccine trials, and identify reagents and
methods for evaluating V1V2 Abs as possible correlates of protection against
HIV-1 infection.TRIAL REGISTRATION: ClinicalTrials.gov NCT00223080.